Valion Bio, Inc. Revenue from Contract with Customer, Excluding Assessed Tax
Valion Bio, Inc. (VBIO) reported Revenue from Contract with Customer, Excluding Assessed Tax of $146.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Income Statement › Revenue
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2025-11-14
- Valion Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $146.00K, a 15.87% increase year-over-year.
- Valion Bio, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2024-09-30 was $126.00K.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month |
|---|---|---|
| 2025-09-30 | $146.00K 10-Q · filed 2025-11-14 | $302.00K 10-Q · filed 2025-11-14 |
| 2024-09-30 | $126.00K 10-Q · filed 2025-11-14 | $600.00K 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |